UNSPSC 51242201: Acetic acid/antipyrine/benzocaine/glycerin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OT900. This VA Drug Class (OT900) classifies this compound as belonging to the group OTIC AGENTS, OTHER.

UNSPSC 51242201 Acetic acid/antipyrine/benzocaine/glycerin (Commodity) encompasses over-the-counter and generic pharmaceutical products that state and local government health facilities, correctional institutions, and related public health operations procure through cooperative purchasing agreements and direct supply arrangements. The code captures finished pharmaceutical products supplied by manufacturers through authorized wholesalers to meet the inventory and dispensing needs of public health systems. Issuing bodies under this code include state departments of health and administration, multistate cooperative purchasing organizations, and subordinate public health facilities and institutions that participate in those cooperative agreements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, functions as a representative buying vehicle that aggregates demand across participating state and local government entities to achieve volume pricing and standardized supplier relationships.

The most recent documented activity appears in the Upper Midwest and Pacific Northwest, where MMCAP solicitation S1070000015802 sought manufacturers of generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities, including Oregon. MMCAP issued an RFP posted January 20, 2026, with proposals due March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and to maintain contractual relationships with at least two of the three wholesalers with chargeback systems in place. Evaluation weighted price competitiveness at 75 percent, with fixed pricing for the contract term, compliance with administrative format requirements, EDI capability, and agreement to a 3 percent administrative fee comprising the remainder. All products required FDA compliance, current Good Manufacturing Practices (cGMP) certification, and Drug Supply Chain Security Act (DSCSA) compliance, with a contract term of two years for new responders and optional extensions at MMCAP's discretion. No specific dollar value or set-aside designations were disclosed in the solicitation materials.